QLT at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam rated QLT Inc. at neutral on news of poor PIER data for Lucentis, although it is expected to emerge as the drug of choice for AMD. Shares of the Vancouver, B.C.-based biopharmaceutical company were down $0.12, or 1.62%, at $7.30 on volume of 427,628 shares versus the three-month running average of 1,036,760 shares. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.